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reduces α-synuclein accumulation in a mouse
model of multiple system atrophy
Brian Spencer1*†, Elvira Valera1†, Edward Rockenstein1, Margarita Trejo-Morales1, Anthony Adame1
and Eliezer Masliah1,2Abstract
Background: Multiple system atrophy (MSA) is a progressive, neurodegenerative disease characterized by
parkinsonism, resistance to dopamine therapy, ataxia, autonomic dysfunction, and pathological accumulation of
α-synuclein (α-syn) in oligodendrocytes. Neurosin (kallikrein-6) is a serine protease capable of cleaving α-syn in the
CNS, and we have previously shown that lentiviral (LV) vector delivery of neurosin into the brain of a mouse model
of dementia with Lewy body/ Parkinson’s disease reduces the accumulation of α-syn and improves neuronal
synaptic integrity.
Results: In this study, we investigated the ability of a modified, systemically delivered neurosin to reduce the levels
of α-syn in oligodendrocytes and reduce the cell-to-cell spread of α-syn to glial cells in a mouse model of MSA
(MBP-α-syn). We engineered a viral vector that expresses a neurosin genetically modified for increased half-life
(R80Q mutation) that also contains a brain-targeting sequence (apoB) for delivery into the CNS. Peripheral
administration of the LV-neurosin-apoB to the MBP-α-syn tg model resulted in accumulation of neurosin-apoB in
the CNS, reduced accumulation of α-syn in oligodendrocytes and astrocytes, improved myelin sheath formation in
the corpus callosum and behavioral improvements.
Conclusion: Thus, the modified, brain-targeted neurosin may warrant further investigation as potential therapy
for MSA.Introduction
The synucleinopathies are a heterogeneous group of
neurodegenerative disorders that affect 5 million people
worldwide and includes Parkinson’s disease (PD), de-
mentia with Lewy bodies (DLB), neurodegeneration
with brain iron accumulation, pure autonomic failure
(PAF) and multiple system atrophy (MSA) (Reviewed in
[1]). Multiple system atrophy is a rapidly progressive,
neurological condition characterized by parkinsonism
resistant to dopamine therapy, ataxia, autonomic dys-
function, and pathological accumulation of α-synuclein
(α-syn) [2–4]. This disorder differs from other synuclei-
nopathies in that α-syn accumulates not only within* Correspondence: b1spencer@ucsd.edu
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in the form of glial cytoplasmic inclusions [5]. This
intracellular accumulation of toxic α-syn species leads
to degeneration of oligodendroglial cells, loss of trophic
support to neurons and subsequent neurodegeneration.
The mechanisms through which α-syn leads to neuro-
toxicity are not completely clear, however recent evidence
supports a role for oligomerization [6, 7]. Increasing evi-
dence supports the notion that α-syn, which is primarily
generated by neurons, can be toxic once released to the
extracellular environment [6, 8, 9]. Extracellular aggregated
α-syn can then propagate to other neurons and glial cells
in a prion-like fashion [10, 11]. Although it had been
previously suggested that the sole source of oligo-
dendroglial α-syn was through endocytosis, a recent
report showed α-syn mRNA in MSA oligodendrocytes
suggesting that the origin of oligodendroglial α-syn
might be both of endogenous nature and the result ofle is distributed under the terms of the Creative Commons Attribution 4.0
.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
ive appropriate credit to the original author(s) and the source, provide a link to
changes were made. The Creative Commons Public Domain Dedication waiver
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cells [12]. Furthermore, propagation and accumulation of
α-syn within astrocytes could lead to activation of these
cells and subsequent neuroinflammation [13–15]. There-
fore, the development of therapeutic interventions for MSA
and related neurodegenerative disorders has been focused
simultaneously on reducing α-syn accumulation, increasing
α-syn clearance and preventing α-syn propagation.
Neurosin, (human kallikrein 6, KLK6, Zyme, Protease
M), is a serine protease capable of cleaving α-syn [16–
19]. This enzyme is found to be expressed throughout
the body in many tissues [20] including the CNS in the
choroid plexus and in oligodendrocytes and astroglial
cells [21] of healthy individuals [20], as well as neurons
and microglia of the hippocampus of Alzheimer’s dis-
ease patients [16, 22]. Down-regulation of neurosin is
associated with accumulation of α-syn in patients with
DLB/PD [23–25] as well in animal models of DLB/PD
[25], whereas over-expression of neurosin in the brain
via lentiviral (LV) vector reduces the accumulation of
α-syn and improves neuronal synaptic integrity in an α-
syn tg mouse model of DLB/PD [25].
Neurosin is expressed as a catalytically inactive pre-
pro protein and is activated through autocatalytic pro-
teolysis. Upon expression and secretion, auto-activation
occurs first via cleavage of the pre-pro neurosin at Q19
followed by cleavage at K21, which produces the mature
neurosin enzyme. The mature neurosin can then auto-
proteolytically inactivate itself with cleavage at R80. This
amino acid, when altered to Glutamine (Q), prevents
the auto-inactivation generating a longer-acting enzyme
[26]. In vitro proteolytic reactions with neurosin show
that autocatalytic cleavage can begin as early as 10 min
after incubation, and full cleavage to the inactive form
occurs by 240 min incubation [26].
Since we have previously shown that stereotaxic injec-
tion of LV-neurosin into the hippocampus reduced the
local accumulation of neuronal α-syn in a mouse model of
DLB [25], for this study we sought to determine if gene
therapy with this vector would also reduce the neuro-
degenerative process in a mouse model of MSA [27, 28].
However, given that the synucleinopathy in MSA is more
disseminated throughout the CNS than PD, a more sys-
temic approach is needed.
For this reason, we engineered the recombinant neuro-
sin for systemic delivery with the R80Q mutation to
allow for longer half-life in order that the active form of
the enzyme would reach the BBB, transcytose the endo-
thelial cells, and reach the site of α-syn accumulation be-
fore it gets degraded. In addition, we fused the 38 amino
acid LDL-R binding domain from apoB; which we have
previously shown to transport active enzymes from the
blood to the brain [29–32]. In this instance we used a
lentiviral vector to deliver the gene for NR-R80Q-apoBto the liver for systemic delivery. The liver acts as a
depot organ to produce and secrete the active enzyme
to the blood stream. Cells expressing large amounts of
the LDL-R, including hepatocytes and Kupffer cells of
the liver, will clear the majority of the recombinant
protein from the blood. Binding to the LDL-R of these
cells will result in clearance by ESCRT-III-mediated
endocytosis leading to lysosomal degradation [29]. In
contrast, at the BBB, the LDL-R will bind the recom-
binant protein and rather than target for degradation,
will transcytose the protein to the neuronal side for
release [33].
In this study, we show that the brain-targeted neuro-
sin accumulated throughout the CNS in neurons, astro-
cytes and microglia, and resulted in reduced accumulation
of α-syn in oligodendrocytes and astrocytes with possible
clearance via microglia. It also ameliorated myelin degen-
eration, neuropathology and behavioral deficits. Thus, the
modified, brain-targeted neurosin may warrant further
investigation as potential therapy for MSA.
Results
Modifications to neurosin increase its stability without
decreasing its ability to degrade α-syn
We have previously shown that neurosin, when expressed
from a lentiviral vector is able to degrade α-syn and
promote the survival of neuronal cells in culture when
challenged with exogenous α-syn [25]. This vector was
delivered by direct stereotaxic injection to an α-syn tg
mouse model of DLB/PD. While this delivery route was
efficient at delivering the enzyme to a localized area of the
mouse brain, a more amenable route of delivery for the
human brain might involve broad blood-based systemic
delivery across the blood-brain barrier (BBB). For this pur-
pose, we engineered neurosin with a novel BBB transport
tag derived from the LDL-R binding domain of Apolipo-
protein B, which we designated apoB [25, 29, 30, 34].
In addition to the apoB modification, the neurosin
we previously delivered by stereotaxic injection was
expressed in the same cells that α-syn was expressed,
so long-lasting enzyme levels were not critically im-
portant to the design. Extracellular neurosin activity is
regulated by an auto-proteolytic inactivation mechan-
ism leading to a short half-life [26]. In order to increase
the half-life of the recombinant protein to allow for sys-
temic delivery and activity in the brain, we engineered a
single point mutation at the site of auto-proteolytic cleav-
age (R80Q) [26]. This new protein was designated neuro-
sin (NR)-R80Q-apoB. All neurosin vectors were tagged
with the V5 epitope tag in order to differentiate recombin-
ant expressed neurosin from endogenous neurosin expres-
sion. The media of cells infected with lentivirus expressing
wild-type neurosin (wt-NR) and wild-type neurosin con-
taining the apoB tag (wt-NR-apoB) contained several
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ity (Fig. 1a). In contrast, the NR-R80Q expressing vec-
tors with or without the apoB tag showed
significantly less auto-proteolysis product in the media
of infected cells indicating an increased stability of
the NR-R80Q (Fig. 1a). The NR-R80Q and NR-R80Q-
apoB vectors were used to infect B103 neuronal cells,
showing similar levels of immunoreactivity compared to
the wt neurosin and wt neurosin-apoB (Fig. 1b, c). In a
co-culture system designed to mimic propagation of α-
syn from cells in the top (α-syn donors) to cells in the
bottom (acceptors) (Fig. 1d), the acceptor cells that
expressed NR-R80Q and NR-R80Q-apoB displayed signifi-
cantly less accumulation of the α-syn secreted from the
neurons in the upper chamber compared to cells express-
ing LV-Control (Fig. 1e, f). Together these results indi-
cate: 1) NR-R80Q is able to reduce the propagation and
accumulation of α-syn in acceptor cells, 2) addition of theFig. 1 Lentivirus vectors over-expressing mutant neurosin reduce the accu
(LV-wt-NR), neurosin-apoB (LV-wt-NR-apoB), the point mutant neurosin (LV-
3rd generation lentivirus vector. a B103 neuronal cells were transduced wit
epitope tag V5. b B103 transduced cells were also immunostained for neur
with the neurosin constructs expressed higher levels of neurosin, levels we
d An in vitro neuronal co-culture system was devised to mimic the propag
LV-Control (red) were plated in cell culture inserts containing a 0.4 μm mem
LV-NR-R80Q-apoB or LV-Control were plated on coverslips. e Confocal mic
the Donor Cells was secreted and taken up by Acceptor cells that were do
analysis of double labeled neuronal cells, results are expressed as percent o
way ANOVA with post hoc Dunnett’s, p < 0.05 compared to LV-Control. # -
compared to LV-wt-NR. Scale bar = (B) 10 μm, (D) 5 μmapoB tag does not impair activity, and 3) the mutated ver-
sion is more stable and active than the wt neurosin.
Neurosin-R80Q-apoB transits to the CNS
Non-tg and MBP-α-syn tg mice received a single intra-
peritoneal injection of LV-Control or LV-NR-R80Q-
apoB and 3 months later they were analyzed for the
trafficking of the fusion protein neurosin-apoB to the
CNS. Whole brain homogenates were fractionated into
soluble and insoluble (membrane-bound) fractions and
assayed by immunoblot for the presence of the recom-
binant neurosin. Neurosin was detected with both a
neurosin-specific antibody and also with a V5 epitope anti-
body that is specific for the NR-R80Q-apoB protein. Mice
treated with the LV-NR-R80Q-apoB displayed higher levels
of neurosin in the soluble fraction compared to mice
injected with the LV-Control (Fig. 2a, b). Comparable levels
of neurosin were detected in non-tg and MBP-α-syn tgmulation and propagation of α-synuclein. Wild-type neurosin
NR-R80Q) and R80Q-apoB (LV-NR-R80Q-apoB) were cloned into the
h the vectors and examined by immunoblot for neurosin and the
osin expression. c Compared to LV-Control, neuronal cells transduced
re comparable between the wt and mutant neurosin constructs.
ation of α-syn. B103 neuronal “Donor cells” infected with LV-α-syn or
brane. B103 neuronal “Acceptor cells” infected with LV-NR-R80Q,
roscopy and immunocytochemical analysis showing α-syn (red) from
uble labeled with an antibody against neurosin (green). f Image
f acceptor cells containing α-syn immunoreactivity. * - indicates one
indicates one way ANOVA with post hoc Tukey-Krammer, p < 0.05
Fig. 2 Neurosin distribution in the brain following systemic administration of LV-Neurosin-apoB vector into MBP-α-syn tg mice. Non-tg and
MBP-α-syn tg mice received a single intra-peritoneal injection of LV-Control or LV-NR-R80Q-apoB (1 × 109 TDU). Three months later mice were
sacrificed, whole blood, CSF and brains were removed with half frozen for protein analysis and half fixed for tissue section immunohistochemistry.
a Representative immunoblot from brain homogenates that were fractioned into soluble and insoluble fractions by ultracentrifugation and
analyzed with antibodies for neurosin and the epitope tag, V5. Neurosin was detected as a double band at approximately 28 kDa. b, c
Densitometry analysis of the levels of neurosin and V5 immunoreactivity plotted against the actin signal. d Hemibrains were serially sectioned
on the longitudinal axis and immunostained with an antibody against neurosin. e Semiquantitative analysis of levels of neurosin immunostaining
in the striatum expressed as optical density. f Representative immunoblot analysis of neurosin in plasma portion of the blood and in whole CSF.
(g, h) Densitometry analysis of neurosin in the blood and CSF. n = 10 mice per group 9–10 m/o at the end of the treatment. * - indicates one
way ANOVA with post hoc Dunnett’s, p < 0.05 compared to non-tg mice that received LV-Control. # - indicates one way ANOVA with post hoc
Tukey-Krammer, p < 0.05 compared to MBP-α-syn tg mice that received LV-Control. Scale bars = Overview 200 μm, Striatum 40 μm
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the V5 antibody, neurosin was only detected in the sol-
uble fraction of mice injected with LV-NR-R80Q-apoB
but not in those injected with LV-Control, as expected
(Fig. 2a, c).
Immunohistochemical analysis showed higher levels
of immunoreactivity in the neocortex, hippocampus
and the striatum in the non-tg and MBP-α-syn tg mice
injected with LV-NR-R80Q-apoB compared to mice
injected with LV-Control (Fig. 2d-e). In addition todetecting the NR-R80Q-apoB in the brain, following LV-
NR-R80Q-apoB systemic injection, higher levels of neuro-
sin immunoreactivity were detected in the blood and CSF
of both non-tg and MBP-α-syn tg mice compared to mice
injected with LV-Control (Fig. 2f-h). Specifically, a 2-fold
increase in neurosin was detected in both the blood
(Fig. 2g) and CSF (Fig. 2h) in animals that received the
systemic LV-NR-R80Q-apoB injection.
We have previously shown that apoB brain-targeted
proteins are taken up by neurons and astrocytes [32]. To
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ized, brain sections from mice treated with LV-Control and
LV-NR-R80Q-apoB were double labeled with antibodies
against the V5 tag in neurosin and the neuronal protein
NeuN, the astrocyte marker GFAP, the microglial cell
marker Iba-1, and the oligodendrocyte protein Olig-2.
Compared to mice injected with the LV-Control, mice
treated with LV-NR-R80Q-apoB displayed increased
neurosin (V5) immunoreactivity in NeuN-positive neu-
rons (Fig. 3a, b), and to a lesser extent increased immu-
noreactivity was also detected in microglia (Fig. 3c, d)
and in astrocytes (Fig. 3e, f ). However, in oligodendro-
glial cells only low levels of neurosin were detected
(Fig. 3g, h). Since the NR-R80Q-apoB is targeted to bind
the LDL-R, we performed co-localization immuno-
staining studies in the brains of the non-tg and MBP-α-
syn tg mice to determine which cells expressed LDL-R
(Additional file 1: Figure S1). LDL-R immunoreactivity
was most abundant in neurons (NeuN), followed by
astrocytes (GFAP) and microglial cells (Iba-1), which
is consistent with the uptake of the NR-R80Q-apoBFig. 3 Cellular uptake of neurosin-apoB in the CNS following systemic deliv
tg received a single i.p. injection with either LV-Control or LV-NR-R80Q-apo
by double immunofluorescence and confocal microscopy for analysis of th
the left depicts the image field zoomed represented under detail. a Double
neuronal marker NeuN (green). Co-immunolabeling is represented by signa
displaying neurosin (V5). c Double immunolabeling for V5 tag to identify n
aided image analysis of the % of microglial cells displaying neurosin (V5) im
neurosin (red) and the astrocytic marker GFAP (green). f Computer aided im
immunostaining. g Double immunolabeling for V5 tag to identify neurosin
aided image analysis of the % of oligodendroglial cells displaying neurosin
per group 9–10 m/o at the end of the treatment. * - indicates one way AN
received LV-Control. Scale bar = 10 μm, detail = 20 μmfusion protein (Additional file 1: Figure S1A, B). In
contrast, oligodendrocytes (p25) showed the lowest
levels of LDL-R immunostaining, suggesting that the
low oligodendroglial uptake of the NR-R80Q-apoB
protein (Fig. 3) is probably related to a low LDL-R
expression (Additional file 1: Figure S1A, B).
Neurosin-R80Q-apoB delivery to the CNS reduces α-syn
accumulation in MBP-α-syn transgenic mouse model
In the MBP-α-syn tg model, α-syn accumulates in oli-
godendrocytes in the neocortex, hippocampus, stri-
atum, corpus callosum and brainstem [27]. To analyze
the effects of the LV-Control or LV-NR-R80Q-apoB
protein products on α-syn accumulation, brain sections
were immunostained with an antibody against total α-
syn (Fig. 4a, b). As expected, in the non-tg mice α-syn
immunoreactivity was diffusely present in a granular
like fashion in the neuropil. Similar levels of α-syn were
detected in non-tg mice treated with LV-Control or LV-
NR-R80Q-apoB, indicating that the viral vector-driven
neurosin has no effects on the levels of endogenous α-ery of the lentivector to MBP-a-syn tg mice. Non-tg and MBP-α-syn
B. Three months later mice were sacrificed and brains were analyzed
e co-localization of neurosin with cellular markers. Dotted box to
immunolabeling for V5 tag to identify neurosin (red) and the
l in yellow. b Computer aided image analysis of the % of NeuN cells
eurosin (red) and the microglial cell marker Iba-1 (green). d Computer
munostaining. e Double immunolabeling for V5 tag to identify
age analysis of the % of astroglial cells displaying neurosin (V5)
(red) and the oligodendrocyte marker Olig-2 (green). h Computer
(V5) immunostaining. All images are from the striatum. n = 10 mice
OVA post hoc Dunnett’s p < 0.05 compared to non-tg mice that
Fig. 4 Delivery of LV-NR-R80Q-apoB reduces α-syn accumulation in MBP-α-syn tg mice. a Bright field microscopy analysis of serial longitudinal
vibratome sections from the non-tg and MBP-α-syn tg mice immunostained with an antibody against total α-syn (syn-1) and analyzed for α-syn
positive cells following treatment with LV-Control, or LV-NR-R80Q-apoB vector. b Computer aided image analysis for numbers of α-syn positive
cells in the striatum and the corpus. c Samples that included the cortex, corpus callosum and striatum were fractioned by ultracentrifugation
and analyzed by immunoblot analysis with an antibody against total α-syn (syn-1). d Densitometry analysis of the levels of α-syn immunor
eactivity plotted against actin. e Laser scanning confocal microscopy of vibratome sections from the non-tg and MBP-α-syn tg immunostained
with an antibody against human α-syn (syn211) and analyzed for α-syn positive cells following treatment with LV-Control, or LV-NR-R80Q-apoB
vector. f Computer aided image analysis of the number of α-syn positive cells in the striatum and the corpus callosum. g Bright field microscopy
analysis of serial longitudinal vibratome sections form the non-tg and MBP-α-syn tg immunostained with an antibody against phosphorylated
α-syn (Ser129) and analyzed for α-syn positive cells following treatment with LV-Control, or LV-NR-R80Q-apoB vector. h Computer aided image
analysis for numbers of phosphorylated α-syn positive cells in the striatum and the corpus callosum. Scale bars – top panels (low power, 40X) = 250 μm,
bottom panel (high power, 400X) = 50 μm. * indicates statistical significance (p < 0.05, one way ANOVA, post hoc Dunnett’s) compared to non-tg mice
LV-control. # indicates statistical significance (p < 0.05, one way ANOVA, post hoc Tukey-Kramer) compared to LV-Control treated MBP-α-syn
tg mice
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munoreactivity was detected in oligodendroglial cells in
multiple brain regions including the striatum and cor-
pus callosum (Fig. 4a, b). Compared to mice injected
with the LV-Control, mice treated with the LV-NR-
R80Q-apoB displayed a trend toward the decrease of α-
syn in the striatum, and a significant reduction in the
corpus callosum (Fig. 4a, b). To further confirm these
findings by an independent method, brain homogenates
were fractioned and analyzed by immunoblot with the
same antibody against total α-syn. Consistent with the
immunohistochemical analysis, levels of α-syn in the
soluble fraction were comparable in the LV-Control
and LV-NR-R80Q-apoB-treated non-tg mice (Fig. 4c, d).
Levels of α-syn in the soluble and insoluble fractions were
higher in the MBP-α-syn tg mice compared to non-tg, as
expected. Treatment with LV-NR-R80Q-apoB resulted in
decreased levels of insoluble α-syn in the MBP-α-syn tg
mice (Fig. 4c, d). Additional confirmation of the results
was performed with a different antibody specific for hu-
man α-syn (SYN211) (Fig. 4e, f ). With this antibody, noendogenous murine α-syn is detected whereas abun-
dant intracellular human α-syn accumulation is
detected in the white matter tracts of the MBP-α-syn
tg mice. Compared to LV-Control, treatment with LV-
NR-R80Q-apoB reduced α-syn in the corpus callosum but
not in the striatum (Fig. 4e, f ). However, there was a sig-
nificant reduction in phosphorylated α-syn (Ser129) in
both the striatum and the corpus callosum (Fig. 4g, h).
Next, we analyzed if the reduced number of α-syn-
containing oligodendrocytes in the animals treated with
LV-NR-R80Q-apoB was related to proximity of these cells
to cells containing the neurosin-apoB and/or to effects at
the mRNA level. Double labeling/co-localization studies
showed a reduction of α-syn in the MBP-α-syn tg mouse
in the areas adjacent to where cells contained high levels
of V5-tagged neurosin in mice that were treated with the
LV-NR-R80Q-apoB vector (Additional file 2: Figure S2).
In contrast, real-time PCR analysis of the MBP-α-syn
tg mice treated with the LV-NR-R80Q-apoB vector
showed no change in the transcription of α-syn
mRNA indicating that the change in α-syn protein
Spencer et al. Molecular Neurodegeneration  (2015) 10:48 Page 7 of 17was due to degradation and not transcriptional alter-
ations (Additional file 3: Figure S3). Consistent with
this finding, double labeling and confocal microscopy
studies with the oligodendroglial marker p25 and α-
syn showed that the total number of oligodendrocytes
were not significantly decreased in the striatum, how-
ever the levels of α-syn per oligodendroglial cell
showed a trend to reduction between animals treated
with LV-Control and LV- NR-R80Q-apoB, although
this reduction was not statistically significant (Add-
itional file 4: Figure S4A, B). Taken together, these re-
sults suggest that the intracellular level of α-syn
within individual oligodendrocytes is not significantly
affected by the treatment, and that the recombinant
neurosin is primarily cleaving the α-syn that propa-
gates from cell-to-cell.
Neurosin-R80Q-apoB reduces the accumulation of α-syn
in astrocytes and α-syn is cleared via microglia
We have previously shown that the astrogliosis and neu-
roinflammation observed in the MBP-α-syn-tg might be
associated with propagation of α-syn from oligodendro-
glial cells to nearby astrocytes similar to propagation ob-
served in MSA [13, 35]. To determine if treatment of
the MBP-α-syn tg mouse with LV-NR-R80Q-apoB could
affect the levels of α-syn in astrocytes, we examined the
levels of α-syn in astroglial cells utilizing double labeling
and confocal microscopy imaging approaches. Consist-
ent with previous studies, in the LV-Control-treated
MBP-α-syn tg mice there was co-localization of α-syn
with the astroglial marker S100 in approximately 12 %
of the cells (Fig. 5a, b). In contrast, treatment with the
LV-NR-R80Q-apoB resulted in a marked decrease in co-
localization of α-syn with the astrocyte marker, S100
(Fig. 5a, b). As expected, no α-syn was detected in the
astrocytes of the non-tg mice. Since in previous studies
we showed that extracellular α-syn can be cleared by
microglial cells, next we performed double labeling and
confocal microscopy imaging studies with the microglial
marker Iba-1 and α-syn (Fig. 5c, d). In the LV-Control
treated MBP-α-syn tg mice, only a few microglial cells dis-
played the presence of α-syn (Fig. 5c, d). In contrast, treat-
ment with the LV-NR-R80Q-apoB resulted in a significant
increase in co-localization between α-syn and the micro-
glial marker Iba-1 (Fig. 5c, d). As expected, no α-syn was
detected in the microglial cells of the non-tg mice. To con-
firm that microglia cells could take up neurosin-digested
α-syn, we incubated oligomeric α-syn with lentivector
expressed NR-R80Q-apoB and added this to BV2 microglia
cells in vitro. Cells that received oligomeric α-syn alone ac-
cumulated α-syn around the periphery with little to no cel-
lular uptake (Additional file 5: Figure S5). In contrast, BV2
microglia cells that received oligomeric α-syn previously
digested with NR-R80Q-apoB showed endocytosis of α-synand this protein was observed in punctate structures in the
cytoplasm (Additional file 5: Figure S5). Taken together,
these results suggest that LV-NR-R80Q-apoB reduced the
accumulation of α-syn in astroglial cells and that microglial
cells were further involved in the clearance of the extracel-
lular α-syn.
Neurosin-R80Q-apoB ameliorates neurodegenerative
pathology in MBP-α-syn tg mice
Previous studies have shown that widespread accumula-
tion of α-syn in oligodendrocytes in the MBP-α-syn tg
mouse model results in neurodegeneration in the cortex
and striatum accompanied by neuroinflammation [27,
28]. For this purpose immunohistochemistry and image
analysis was utilized to determine if delivery of the NR-
R80Q-apoB would ameliorate the neuropathology and
neuroinflammation. Consistent with previous results,
compared to non-tg mice, MBP-α-syn tg mice treated
with LV-Control displayed a significant reduction in
NeuN cell counts in the striatum but only a trend in the
frontal cortex; treatment with the LV-NR-R80Q-apoB
ameliorated the loss of NeuN cells in the striatum to
values similar to those observed in non-tg animals
(Fig. 6a-c) treated with the LV-Control or LV-NR-R80Q-
apoB vectors. In agreement with these results, compared
to non-tg mice, the MBP-α-syn tg mice treated with LV-
Control showed significant astrogliosis (GFAP) in the cor-
pus callosum and striatum. Treatment with the LV-NR-
R80Q-apoB vector significantly reduced astrogliosis in the
corpus callosum and striatum to values similar to those ob-
served in non-tg animals (Fig. 6d-f). At the age these ani-
mals were analyzed microgliosis was also not altered in
either the frontal cortex or striatum of MBP-α-syn tg mice
when compared to non-tg controls. Treatment with the
LV-NR-R80Q-apoB vector did not appear to alter micro-
gliosis in either treated animal group indicating that the
treatment itself does not promote an adverse inflammatory
response (Fig. 6g-i, Additional file 6: Figure S6).
Neurosin-R80Q-apoB ameliorated myelination deficits in
the MBP-α-syn tg mice
The accumulation of α-syn in oligodendroglial cells is as-
sociated with demyelination in patients with MSA [36].
To examine the effect of treatment with LV-NR-R80Q-
apoB on myelination in the MBP-α-syn tg mice, sections
were stained with luxol fast blue (LFB) and myelination
was analyzed in the neocortex, corpus callosum (Fig. 7a,
b) and striatum. Consistent with previous studies in these
mice [27, 28], the MBP-α-syn tg mice display reduced
levels of staining with LFB in the corpus callosum com-
pared to non-tg controls (Fig. 7a), indicative of myelin dis-
ruption in these mice. Treatment of the MBP-α-syn tg
mice with LV-NR-R80Q-apoB was associated with in-
creased levels of LFB staining in both neocortex and
Fig. 5 Delivery of LV-NR-R80Q-apoB reduces the propagation of α-syn to astrocytes and clearance via microglia in MBP-α-syn tg mice.
Vibratome brain sections from the non-tg and MBP-α-syn tg that received i.p. injections of LV-Control or LV-NR-R80Q-apoB were double
immunofluorescence labeled with antibodies against cellular markers and human α-syn and analyzed with the laser scanning confocal
microscope with an optical image of 1 μm with fluorescent signals in co-registry. Dotted box to the left depicts the image field zoomed
represented under detail. a Double immunolabeling for the astrocyte marker S100 (red) and human α-syn (green) with nuclei (DAPI, blue).
Co-immunolabeling is represented by signal in yellow. b Computer aided image analysis of the % of S100 cells displaying α-syn immuno-
fluorescence in the corpus callosum and striatum. c Double immunolabeling for the microglial marker Iba-1 (red) and human α-syn (green)
with nuclei (DAPI, blue). Co-immunolabeling is represented by signal in yellow. d Computer aided image analysis of the % of Iba-1 cells displaying
α-syn immunofluorescence in the corpus callosum and striatum. n= 10 mice per group 9–10 m/o at the end of the treatment. Scale bar = 10 μm,
detail = 20 μm. # indicates statistical significance (p< 0.05, one way ANOVA, post hoc Tukey-Kramer) compared to LV-Control treated MBP-α-syn tg mice
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Fig. 6 Delivery of LV-NR-R80Q-apoB ameliorates the neurodegenerative pathology in MBP-α-syn tg mice. Serial longitudinal vibratome sections
were analyzed by bright field microscopy. Top row represents a low power overview (40X) of the section and panels in the bottom row show a
higher magnification view (400X) of the striatum. a Immunohistochemical analysis with an antibody against the neuronal marker NeuN in brain
sections of non-tg mice or MBP-α-syn tg mice injected with LV-Control, or LV-NR-R80Q-apoB vector. b, c Stereological analysis using the dissector
method to estimate the total numbers of NeuN-positive cells in the frontal cortex and striatum. d Immunohistochemical analysis with an antibody
against the astrocyte marker GFAP in brain sections of non-tg mice or MBP-α-syn tg mice injected with LV-Control, or LV-NR-R80Q-apoB vector.
e, f Semiquantitative analysis of levels of GFAP immunostaining by optical density in the corpus callosum and striatum. g Immunohistochemical
analysis with an antibody against the microglial marker Iba-1 in brain sections of non-tg mice or MBP-α-syn tg mice injected with LV-Control, or
LV-NR-R80Q-apoB vector. h, i Stereological analysis using the dissector method to estimate the total numbers of Iba-1 positive cells in the frontal
cortex and striatum. n = 10 mice per group 9–10 m/o at the end of the treatment. Scale bar = in the lower magnification panels 250 μm and in
the higher magnification panels 50 μm. * indicates statistical significance (p < 0.05, one way ANOVA, post hoc Dunnett’s) compared to LV-control,
non-tg mice. # indicates statistical significance (p < 0.05, one way ANOVA, post hoc Tukey-Kramer) compared to LV-Control treated MBP-α-syn
tg mice
Spencer et al. Molecular Neurodegeneration  (2015) 10:48 Page 9 of 17striatum (Fig. 7a, b) to values similar to non-tg controls.
These results were further confirmed by analysis of the
myelin sheaths by electron microscopy in corpus callosum
(Fig. 7c). In the non-tg mice, the myelin sheath can be ob-
served as a highly organized multilaminar structure (Fig. 7c).
In the LV-Control MBP-α-syn tg mice, myelinated axons
were reduced, the myelin sheath had fewer layers and was
substantially more disorganized compared to the non-tg
mice (Fig. 7c). In the MBP-α-syn tg mice treated with LV-
NR-R80Q-apoB, the number of myelinated axons as well as
the number of myelin layers per axon were preserved and
their levels were comparable to non-tg controls (Fig. 7c, d).
Immunoblot analysis of myelin basic protein (MBP)
from dissected brain homogenates revealed a signifi-
cant reduction in total MBP protein in the LV-Controltreated MBP-α-syn tg mice compared to non-tg mice
(Fig. 7e, f ). Treatment with LV-NR-R80Q-apoB in-
creased levels of MBP protein to levels greater than
those in non-tg mice (Fig. 7e, f ). The MBP protein
levels increased at the post-transcriptional level, as
real-time PCR analysis of the LV-NR-R80Q-apoB
treated MBP-α-syn tg mice showed no change in
transcription levels of MBP mRNA (Additional file 2:
Figure S2B). Furthermore, CNP protein expression is
associated with increased oligodendrocytes process
extension and myelination [37]. Compared to the LV-
Control-injected MBP-α-syn tg mice, CNP protein
levels were increased in MBP-α-syn tg mice treated
with LV-NR-R80Q-apoB indicating that the presence
of elevated neurosin improved the oligodendroglial
Fig. 7 Delivery of LV-NR-R80Q-apoB reduces demyelination in MBP-α-syn tg mice. a Vibratome brain sections were stained with luxol fast blue
(LFB) and analyzed by bright field microscopy. The panel in the top is a lower magnification view (40X) showing myelin in blue in white matter
tracks. The bottom panels are higher magnification (400X) of the corpus callosum of non-tg mice or MBP-α-syn tg mice treated with LV-Control
or LV-NR-R80Q-apoB. Scale bars = Overview 250 μm, corpus callosum 50 μm. b Semiquantitative analysis of LFB staining by optical density in the
corpus callosum. c Transmission electron microscopy (TEM) images of myelin sheaths in the corpus callosum of non-tg mice or MBP-α-syn tg
mice treated with LV-Control or LV-NR-R80Q-apoB. Representative micrographs taken with TEM are shown at low magnification (5,000x) and high
magnification (25,000x). Scale bars = Overview 2.5 μm, Corpus callosum 500 nm. d Computer aided image analysis of the number of myelinated
axons in corpus callosum. e Tissue blocks containing the corpus callosum and striatum were fractioned by ultracentrifugation and analyzed by
immunoblot with antibodies against MBP and CNP. (f) Densitometric analysis of the MBP and CNP signal normalized to the actin signal.
* indicates statistical significance (p < 0.05, one way ANOVA, post hoc Dunnett’s) compared to LV-Control treated Non-tg mice. n = 10 mice per
group 9–10 m/o at the end of the treatment. # indicates statistical significance (p < 0.05, one way ANOVA, post hoc Tukey-Kramer) compared to
LV-Control treated MBP-α-syn tg mice
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model (Fig. 7e).
Neurosin-R80Q-apoB reduces behavioral deficits in MBP-
α-syn tg mice
The neurodegenerative pathology (neuronal loss, astro-
gliosis and demyelination in the corpus callosum) in the
MBP-α-syn tg mice is accompanied by behavioral defi-
cits specifically locomotor activity [38] similar to symp-
toms observed in MSA [3, 39]. In order to investigate
the functional effects of the treatment with the LV-NR-R80Q-apoB, mice were examined in the open field test;
a behavioral test that examines both anxiety as well as
locomotor activity in MSA transgenic mice [38]. At first,
total activity after consecutive days was examined; this is
a test of habituation to a novel environment and of
memory acquisition. The non-tg mice treated with LV-
Control or LV-NR-R80Q-apoB rapidly acclimated to the
new environment as reflected by the reduced activity
over time (Fig. 8a). In contrast the LV-Control-treated
MBP-α-syn tg mice did not habituate and activity
increased over time, whereas the MBP-α-syn tg treated
Fig. 8 Treatment with LV-NR-R80Q-apoB improves the behavioral deficits in MBP-α-syn tg mice. Non-tg mice or MBP-α-syn tg mice treated with
LV-Control or LV-NR-R80Q-apoB were tested in the open field test for 4 successive days or for a fixed period to ascertain the functional effects of
LV-NR-R80Q-apoB treatment. a Total activity after consecutive days was performed, this is a test of habituation to a novel environment and of
memory acquisition. b Retention score analysis representing the ratio between trials 3 and 4. c Total spontaneous activity after 10 min in the
open field test. d Total activity in the center of the cage, no differences were noted among the 4 groups. n = 10 mice per group 9–10 m/o at the
end of the treatment. Scale bar = 10 μm. * indicates statistical significance (p < 0.05, one way ANOVA, poshoc Dunnett’s) compared to non-tg
mice. # indicates statistical significance (p < 0.05, one way ANOVA, post hoc Tukey-Kramer) compared to LV-Control treated MBP-α-syn tg mice
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mice (Fig. 8a). These findings were consistent with the
retention score analysis, which is the ratio between trials
3 and 4 (Fig. 8b). Next, total spontaneous activity for 10
min was analyzed. As expected, the LV-Control treated
MBP-α-syn tg displayed hyper-activity compared to non-
tg, however the MBP-α-syn tg mice treated with LV-NR-
R80Q-apoB behaved similar to the non-tg controls
(Fig. 8c). No differences were noted among the 4 groups
in time expended in the center of the cage (Fig. 8d).
These results further suggest that gene therapy using a
modified, brain-targeted neurosin have beneficial effects
on cognition in this tg mouse model of MSA.
Discussion
We have developed a novel brain penetrating neuro-
sin protein for systemic delivery to the CNS with the
potential for treatment of synucleinopathies. In
addition to the stabilizing point mutation (R80Q),
our fusion protein contained a C-terminal apoB tag
that facilitates trafficking of the protein into the CNS
via the LDL-R. We showed that the LV-NR-R80Q-
apoB reduced the accumulation of α-syn and the
propagation of α-syn from oligodendrocytes to astro-
glia, ameliorated the neurodegenerative pathology in-
cluding myelination and reversed the behavioral
deficits in the MBP-α-syn tg mouse model of MSA.This is the first application of this stabilized neurosin
for a therapeutic purpose and represents a novel ap-
proach for treatment of a unique synucleinopathy
that affects to a greater extent the oligodendrocytes.
We chose to test the NR-R80Q-apoB in an MSA
model because this construct distributes in multiple
brain regions and in MSA there is more diffuse and
widespread disease when compared to other synuclei-
nopathies such as PD.
Although neurosin is predominantly expressed in the
CNS, many kallikreins exhibit aberrant expression in
peripheral tumors such as those of breast and prostate.
Interestingly, in both these tumors there is a reduced ex-
pression of the kallikreins PSA, kallikrein 6 and NES1
that is associated with cell outgrowth, suggesting that
kallikrein expression may have an anti-tumor function in
these tissues. In fact, recent investigation of KLK5 has
shown that expression in breast tissue regulates several
anti-oncogenic miRNAs [40, 41]. In the CNS, neurosin
displays remarkably restricted substrate specificity, lack-
ing chymo-, trypsin-, urokinase-, or elastase- specific
substrate specificity. In fact, other than α-syn, the pri-
mary CNS substrate appears to be PAR-2 where cleavage
occurs at S37 to activate the receptor; however, neurosin
fails to activate PAR-1 or PAR-4. Activation of PAR-2 by
excess neurosin could be potentially harmful to neurons
as it elicits elevations in intracellular Ca+ levels [42], and
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toxic in cultured hippocampal neurons [43]. However, in
this study examination of neuronal cells immunolabeled
with NeuN did not show any significant loss of neurons
following systemic NR-R80Q-apoB; on the contrary, we
found a rescue effect. Further studies should examine
off-target effects such as these.
Neurosin protein expression is observed in oligo-
dendrocytes with reduced expression during demyelin-
ation [21, 44] and knockout of neurosin reduces MBP
protein in the spinal cord of experimental mice indi-
cating that neurosin regulates myelination via MBP
[45]. Although the exact role of neurosin activity on
myelination or maturation of MBP is not known, we
did observe an increase in myelination and MBP fol-
lowing delivery of the recombinant NR-R80Q-apoB to
the MBP-α-syn tg mouse. This is consistent with the
possibility that neurosin might improve the demyelin-
ation phenotype in the mice by modulating MBP.
This was observed both by electron microscopy and
LFB staining of the corpus callosum. Interestingly, we
did not observe increased neurosin protein in the oli-
godendrocytes; however, we did observe a reduction
in the number of α-syn positive oligodendrocytes in
the corpus callosum. This is probably due to the lack
of LDL-R on these cells preventing the uptake of the
neurosin-apoB fusion protein. In addition, we did not
observe a change in the expression of the MBP
mRNA, suggesting that the change in MBP we ob-
serve is at the post-transcriptional level. The in-
creased MBP in the corpus callosum may be due to
effects of extracellular neurosin directly on MBP ei-
ther by stabilizing or by processing the protein. Alter-
natively, the increased MBP may be due to an overall
increase in the overall health of oligodendrocyte cells due
to an improvement in the extracellular environment caused
by the reduction of extracellular α-syn by neurosin.
Neurosin is a soluble extracellular protease without a
native receptor-binding domain [18]. The addition of the
LDL-R binding domain of apolipoprotein B not only
targets the recombinant protein for transport across the
BBB, but also for uptake by cells expressing the LDL-R.
These include neurons, astrocytes and microglial cells and
to a much lesser extent oligodendrocytes as evidenced by
the LDL-R immunolabeling in this study. We have previ-
ously shown similar penetration into the CNS via LDL-R
in endothelial cells in the BBB with other proteases such
as neprilysin (amyloid β degrading enzyme) [30, 31] and
with single chain antibodies targeting α-syn oligomers
[29]. For the present study, we showed that delivery
of brain-targeted neurosin resulted in decreased α-syn
accumulation in oligodendrocytes and astrocytes with
a concomitant localization in microglia. Given that in
our model α-syn is only expressed in oligodendroglialcells, but is localized in astrocytes, one potential hy-
pothesis for the reduction is that neurosin decreases
the transfer of α-syn from oligodendrocytes to astro-
glia with clearance via microglia. The reduced α-syn
transfer could be related to a reduction in extracellu-
lar α-syn (“sink effect”) (Fig. 9a, b). In support of this
possibility we show that microglial cells are able to de-
grade α-syn in the presence of neurosin. This is consist-
ent with previous studies showing that among other
CNS cells, microglial cells are most effective at clearing
α-syn [46–48]. Furthermore, the fact that neurosin is also
able to penetrate astroglial and microglial cells through
interaction of the apoB domain with LDL-R suggest that
neurosin might also be degrading intracellular α-syn in
those cell types in addition to extracellular α-syn (Fig. 9).
Therefore without specific intracellular oligodendro-
cyte α-syn degradation, we still observed reduced ac-
cumulation of α-syn in the brain, reduced astrocyte
α-syn uptake and/or accumulation, and improved
oligodendrocyte health as observed by increased mye-
lin and MBP expression. A further benefit of decreased
extracellular α-syn would be decreased activation of
astroctyes [49].
Without specific evidence that neurosin is degrading
α-synuclein extracellularly or intracellularly, we cannot
definitively rule out other hypotheses and it is clear that
further experimental data is needed to better understand
how neurosin reduces α-syn in astrocytes. However,
neurosin taken up by astrocytes via the LDL-R would be
targeted to the lysosome through native LDL-R pathway
leading to an acidic environment [50]. Neurosin is
known to function best in a neutral environment [51]
providing further evidence that little if any α-synuclein
degradation would be occurring in astrocyte lysosomes
and instead most would be occurring in the extracellular
environment.
Taken together these findings suggest that this
might be the result of a combination of reduced
extracellular α-syn and reduced propagation of α-syn.
Interestingly, double labeling studies showed co-
localization of α-syn to microglial cells in the MBP-α-
syn mice treated with LV-NR-R80Q-apoB, suggesting
that in the presence of neurosin, extracellular α-syn
was cleared via the microglia. This is consistent with
previous studies using anti-α-syn antibodies showing
that microglial cells are capable of clearing α-syn
[46–48]. A recent study showed that neurosin had re-
duced degradation of extra-cellular α-syn when in the
presence of lipids or fatty acids [52]. The reduction in
total α-syn we observed might be due to higher than
normal levels of neurosin in the extra-cellular envir-
onment leading to proteolysis, increased degradation
by microglia or increased intra-cellular proteolysis in
astrocytes.
Fig. 9 Hypothesis of the effects of treatment with LV-NR-R80Q-apoB in MBP-α-syn tg mice. In the MBP-α-syn tg model of MSA, oligodendrocytes
express high levels of α-syn and release it to the extracellular environment, where it can propagate to astroglial cells or be taken up by microglial
cells for degradation. The modified, brain-targeted fusion protein NR-R80Q-apoB (neurosin-apoB) is able to access and degrade extracellular α-syn,
as well as be internalized by astroglia and microglia, potentially degrading also intracellular α-syn in those cell types. In LV-Control-treated tg mice
(a), α-syn propagates and accumulates within astroglial cells. However in LV-NR-R80Q-apoB-treated tg animals neurosin degrades extracellular
α-syn (b), thus stimulating further release of α-syn from oligodendroglial cells (“sink effect”), reducing its propagation and accumulation in
astroglia, and inducing its uptake and degradation by microglia
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Considering many synucleinopathies involve the accumu-
lation of α-syn in neurons, astrocytes and oligodendroglial
cells and involve the propagation of α-syn from cell-to-
cell, the use of NR-R80Q-apoB should be considered a
potential therapeutic for other synucleinopathies such as
PD and DLB. Systemic delivery of the recombinant pro-
tein by intra-peritoneal infusion followed by transport
across the BBB for treatment of the whole brain would
facilitate a non-invasive and broad-based therapeutic
option for numerous α-syn related pathologies.
Methods
Construction of lentivirus vectors
The mouse Neurosin cDNA (Open Biosystems) was
PCR amplified and cloned into the third generation
self-inactivating lentivirus vector [53] with the CMV
promoter driving expression producing the vector LV-
Neurosin as previously described [25]. The lentivirus
vector expressing the human wild-type α-syn has been
previously described. The R80Q neurosin mutation
was generated as described [26] using the QuikChange
Lightning Site-Directed Mutagenesis Kit (Agilent Tech-
nologies). Addition of the 38 amino acid apoB LDL-Rbinding domain to the c-terminus of both wild-type neu-
rosin and the R80Q neurosin was performed by site di-
rected mutagenesis addition of a unique AgeI restriction
site in frame followed by cloning of the oligonucleotide
coding for the apoB peptide [29, 30, 32]. Lentiviruses ex-
pressing the neurosin (LV-wt-NR), neurosin-apoB (LV-wt-
NR-apoB), neurosin R80Q (LV-NR-R80Q), neurosin
R80Q-apoB (LV-NR-R80Q-apoB, α-synuclein (LV-α-syn)
or empty vector (LV-Control) were prepared by transi-
ent transfection in 293T cells [53].
Establishment of in vitro cultures
For these experiments we used the rat neuroblastoma
cell line B103. This model was selected because over-
expression of α-syn in these cells results in mitochon-
drial alterations, reduced cell viability, defective neurite
outgrowth and abnormal accumulation of oligomeric α-
syn [54]. For all experiments, cells were infected with
LVs at a multiplicity of infection (MOI) of 20.
The B103 cells were grown as described above and
plated onto poly L-lysine coated glass coverslips at a
density of 5 × 104 cells. Five hours after plating, cells
were infected with the LV-Neurosin vectors and incu-
bated for 48 h. Control experiments were performed
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lysis, 5 × 104 B103 cells were plated onto poly L-lysine
coated glass coverslips and infected with LV-Neurosin
vectors or onto 12 well cell culture inserts containing a
0.4 μm PET membrane (Fisher Scientific) and infected
with LV-α-syn vectors. Cultures were incubated separately
for 6 h to allow cells to attach and then co-cultured until
analysis.
BV2 microglia cells were grown as previously de-
scribed [46] and plated on poly L-lysine coated glass
coverslips at a density of 5 × 104 cells for 24 h. Cultured
supernatent from LV-NR-R80Q-apoB or LV-Control in-
fected B103 cells was collected and passed through a
0.22 μm filter to remove any cells. The supernatent was
then incubated with 500nM of previously oligomerized
α-syn [25] for 32 h at 37 °C and then added to BV2 cells
for 1 h at 37 °C, 5 % CO2. At the conclusion of all exper-
iments, cells were washed twice with ice-cold PBS
followed by fixation with cold 4 % PFA.
Treatment of animals
Mice expressing human α-syn under the control of the
Myelin Basic Protein (MBP) promoter (MBP-α-syn tg)
were generated as previously described [27]. In this
study we used the MBP1 line, as animals express an
intermediate level of α-syn compared to the other lines
and they are more viable and less aggressive. MBP-α-syn
tg mice develop progressive accumulation of α-syn in-
clusions in oligodendrocytes along the axonal tracts in
the brainstem, basal ganglia, cerebellum, corpus callo-
sum, and neocortex, leading to neurodegeneration in the
neocortex and to loss of dopaminergic fibers in the basal
ganglia. Non-tg and MBP-α-syn tg mice received a single
intra-peritoneal injection of LV-Control (1.0 × 109 TDU/
mouse) or LV-NR-R80Q-apoB (1.0 × 109 TDU/mouse)
(n = 10/group) in a volume of 300 μl. We, and others
have previously shown that this method of vector
delivery results in lentiviral transduction of the liver
(sinusoidal cells and to a lesser extent hepatocytes) and
the spleen (splenocytes) where the secreted protein is
expressed and transported by the blood to the blood–
brain barrier [32, 55]. Treatment lasted 3 months with
all mice between 9 and 10 months of age by the end of
the study. All experiments were carried out in accord-
ance with the guidelines laid down by the NIH regarding
the care and use of animals for experimental procedures
and approved by the Institutional Animal Care and Use
Committee at the University of California at San Diego
(UCSD) under protocol #S02221.
Behavioral analysis
Context-dependent learning in an open field was analyzed
using a Kinder SmartFrame Cage Rack Station activity
monitor system (Kinder Scientific, Poway, CA), in3-dimensional space using a 7 × 15 beam configuration.
Data collection began when an animal was placed in the
test chamber. Animals were evaluated for 10 min for three
consecutive days, given a two-day dishabituation period,
followed by a fourth trial [56].
Real-time PCR analysis
Total RNA was extracted from the mouse anterior hemi-
brain using a Qiagen RNeasy kit and following the in-
structions of the manufacturer. RNA concentration was
determined and 0.5 μg of RNA per sample were used for
reverse transcription to cDNA using a High capacity
cDNA reverse transcription kit (Applied Biosystems).
cDNA solutions were diluted 1:10 in ultrapure water
and 4 μl of this dilution were used per reaction. Real
time PCR (qPCR) was performed using Fast SYBR Mas-
ter Mix and primers for human α-syn, mouse MBP,
TNFα, IL-1ß, IL-6, IL-10 and ß-actin as internal control
[35, 57]. qPCR reactions were run in a StepOnePlus
Real-Time PCR system (Applied Biosystems) and ΔΔCt
calculations were made using StepOne software (Applied
Biosystems).
Immunoblot analysis
Hemibrains were homogenized and divided into cyto-
solic and membrane fractions as previously described
[54, 58]. For immunoblot analysis, 20 μg of total protein
per lane was loaded on 4–12 % Bis-Tris SDS-PAGE gels
and blotted onto polyvinylidene fluoride membranes.
Membranes were probed with antibodies against full-
length human α-syn (SYN211, Life Technologies), hu-
man neurosin (R&D Systems) or the epitope tag V5 (Life
Technologies). Incubation with primary antibody was
followed by species-appropriate incubation with second-
ary antibody tagged with horseradish peroxidase (Santa
Cruz Biotechnology) and visualization with enhanced
chemiluminescence.
Heparinized blood (plasma) (diluted 1:10 in PBS) and
CSF (undiluted) samples were loaded on 4-12 % Bis-Tris
SDS-PAGE gels and blotted onto polyvinylidene fluoride
membranes and probed with antibodies against human
neurosin (R&D Systems) as described above. Analysis of
all immunoblot was performed with a Versadoc XL
imaging apparatus (BioRad) using β-actin (Sigma) levels
as a loading control.Immunohistochemistry and electron microscopy
At the end of the experiment, CSF and blood were col-
lected and animals were transcardially perfused with
physiological saline and brains were collected. Brains
were divided sagittally into right and left hemibrains.
The left hemibrain was fixed in 4 % paraformaldehyde in
Spencer et al. Molecular Neurodegeneration  (2015) 10:48 Page 15 of 17phosphate buffered saline and serially sectioned in the
vibratome at 40 μm and stored at −20 °C in cryoprotec-
tive medium. The right hemibrain was snap-frozen and
stored at −80 °C for subsequent protein extraction. Sec-
tions were immunostained with antibodies against α-syn
(Chemicon), NeuN (neuronal marker, Millipore), GFAP
(astroglial marker, Millipore), Iba-1 (microglia, Wako),
Olig-2 (oligodendrocytes, Cell Signaling) and p25 (oligo-
dendrocytes, IBL) and imaged with an Olympus BX54
bright field digital microscope or a laser scanning confocal
microscope. Digital images were analyzed with the Image-
Quant 1.43 program (NIH) to determine numbers of
α-syn aggregates, neurons, astrogliosis and microgliosis
[28, 46]. A minimum of 100 cells with 4 fields were
counted per animals and expressed as the average number
of positive cells per field (230 μm× 184 μm). Stereological
analysis of NeuN, Iba-1 and α-syn immunoreactivity was
conducted by the dissector method using the Stereo-
Investigator System (MBF Bioscience), and the results
were averaged and expressed as cell counts per 0.1 mm3.
Additional sections were stained with luxol fast blue (LFB,
Acros) in order to visualize the myelin layers and imaged
on the Olympus BX54 bright field digital microscope [59].
Optical density measurements were obtained using the
ImageQuant software, and quantification performed by
correcting against background signal levels.
For electron microscopy, vibratome sections were
postfixed in 1 % glutaraldehyde, treated with osmium
tetraoxide, embedded in epon araldite and sectioned
with the ultramicrotome (Leica). Grids were analyzed
with a Zeiss OM 10 electron microscope as previously
described [54]. Cells were randomly acquired from 3
grids, and electron micrographs were obtained at a mag-
nification of 5,000X and 25,000X.
Double immunolabeling and confocal microscopy
To determine the co-localization between α-syn or neu-
rosin and cellular markers, double-labeling experiments
were performed as previously described [25]. Vibratome
sections were immunolabeled with antibodies against
S100 (astroglia), Iba1 (microglia), Olig-2 (oligodendro-
cytes), p25 (oligodendrocytes) or NeuN (neurons), and
the immunoreactive structures were detected with
FITC-tagged secondary antibody (Vector Laboratories,
1:75) and the V5 tagged neurosin with the Tyramide Sig-
nal Amplification™-Direct system (NEN Life Sciences),
while α-syn was detected with an antibody specific for
human α-syn (SYN211, Sigma) and a FITC-tagged
secondary antibody (Vector Laboratories, 1:75). Cell nu-
clei were stained using ProLong® Gold Antifade with DAPI
(4',6-diamidino-2-phenylindole) (Molecular Probes). Sec-
tions were imaged with a Zeiss 63X objective on an Axio-
vert 35 microscope (Zeiss) with an attached MRC1024
laser scanning confocal microscope (BioRad) with anoptical image of 1 μm thick with fluorescent signals in co-
registry [60].
Statistical analysis
Values are expressed as average ± standard error of the
mean (SEM). To determine the statistical significance we
used one-way analysis of variance with post-hoc Dunnett’s
test when comparing to the control condition. Additional
comparisons were done using Tukey-Kramer or Fisher
post hoc tests. The differences were considered to be
significant if p values were less than 0.05.
Additional files
Additional file 1: Figure S1 Analysis of LDL-R expression in the brain
of MBP-α-syn tg mice. Vibratome brain sections were analyzed by
double immunofluorescence and confocal microscopy for analysis of the
co-localization between LDL-R (red) and cellular markers (green). Dotted
box to the left depicts the image field zoomed represented under detail.
(A) Laser scanning confocal microscopy of sections from MBP-α-syn tg
immunostained with LDL-R (red) and antibodies against NeuN (neurons),
p25 (oligodendrocytes), GFAP (astrocytes) and Iba-1 (microglia) (red).
(B) Computer aided image analysis for the % of cells displaying
co-localization of LDL-R and cellular markers. n = 10 mice per group.
Scale bar = 10 μm. (TIFF 3556 kb)
Additional file 2: Figure S2 Neurosin co-localizes with α-syn in the
striatum. Laser scanning confocal microscopy analysis of sections double
labeled with antibodies against V5 tagged neurosin (red) and α-syn
(green) in the striatum of non-tg and MBP-α-syn tg mice injected with
LV-Control or LV-NR-R80Q-apoB. Dotted box to the left depicts the image
field zoomed represented under detail. Scale bar = 10 μm. n = 10 mice
per group 9–10 m/o at the end of the treatment. (TIFF 1909 kb)
Additional file 3: Figure S3 Real time PCR analysis of MBP and α-syn
expression in MBP-α-syn tg mice. Real-time PCR analysis of gene expression
in non-tg and MBP-α-syn tg mouse brain tissue after treatment with LV-
Control or LV-NR-R80Q-apoB. Total RNA was extracted and used for
real-time PCR analysis using either primers specific for (A) MBP or (B)
human α-syn. Gene expression signal was normalized to β-actin signal.
n = 4 mice per group. (TIFF 371 kb)
Additional file 4: Figure S4 Levels of α-syn immunoreactivity in
individual oligodendroglial cells in the brains of MBP-α-syn tg that
received LV-NR-R80Q-apoB. Vibratome brain sections were analyzed by
double immunofluorescence and confocal microscopy for analysis of
the levels of human α-syn (red) in oligodendroglial cells labeled with an
antibody against p25 (green). Dotted box to the left depicts the image field
zoomed represente
d under detail. (A) Laser scanning confocal microscopy of sections from non-
tg and MBP-α-syn tg immunostained with human α-syn (red) and p25 (green).
(B, C) Computer aided image analysis of p25 positive
oligodendrocytes expressed as numbers per 103 in the striatum and of the
levels of α-syn in individual p25 positive cells expressed as pixel intensity.
n= 10 mice per group. Scale bar = 30 μm. (TIFF 2838 kb)
Additional file 5: Figure S5 Microglia endocytose extracellular α-syn
digested by neurosin. BV2 microglia cells were analyzed by double
immunofluorescence and confocal microscopy for Iba1 (green) and α-syn
(red). BV2 cells were incubated with oligomeric α-syn with or without
pre-incubation with cultured supernatent from LV-NR-R80Q-apoB infected
B103 neuronal cells. Dotted box to the left depicts the image field
zoomed represented under detail. Scale bar = 20 μm. (TIFF 8074 kb)
Additional file 6: Figure S6 NR-R80Q-apoB does not significantly
affect expression levels of CNS cytokines. Real-time PCR analysis of gene
expression in non-tg and MBP-α-syn tg mouse brain tissue after
treatment with LV-Control or LV-NR-R80Q-apoB. Total RNA was
extracted and used for real-time PCR analysis using either primers
Spencer et al. Molecular Neurodegeneration  (2015) 10:48 Page 16 of 17specific for (A) TNFα, (B) IL-1ß, (C) IL-6 or (D) IL-10. Gene expression
signal was normalized to β-actin signal. n = 4 mice per group.
(TIFF 4474 kb)
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